BG Medicine, Inc.

BG Medicine Files US Registration Statement with SEC in Support of Euronext Amsterdam IPO

BG Medicine Files US Registration Statement with SEC in Support of Euronext Amsterdam IPO

August 6, 2007

WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine, Inc. today announced it has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission (SEC) for a proposed Initial Public Offering (IPO) of its common stock. All of the shares to be offered will be sold by the company. The number of shares to be sold and the price range for the offering have not yet been determined. BG Medicine intends to apply for its common stock to list and trade on Euronext Amsterdam by NYSE Euronext under the symbol “BGMDX”.

Epitome Biosystems

Epitome Biosystems Launches Ti-Tyr™ Profiling Chips for Simultaneous Measurement of Multiple Cellular Events

Epitome Biosystems Launches Ti-Tyr™ Profiling Chips for Simultaneous Measurement of Multiple Cellular Events

August 7, 2007

Waltham, MA, August 7, 2007 – Epitome Biosystems announced today the commercial launch of its Ti-Tyr™ Phosphorylation Profiling Chip, providing researchers with substantially increased capabilities for measuring cellular activities in their drug discovery and development efforts. Ti-Tyr™ Chips enable specific, cell-based measurements of biological function to be made quickly and in a highly multiplexed format, increasing the amount of relevant data generated per sample.

LS9

LS9, Inc., the Renewable Petroleum Company™, Adds Charles Cooney to Board of Directors

LS9, Inc., the Renewable Petroleum Company™, Adds Charles Cooney to Board of Directors

August 8, 2007

SAN CARLOS, Calif., Aug. 8 /PRNewswire/ -- LS9, Inc., the Renewable Petroleum Company™, today announced that the company has appointed Charles L. Cooney to its Board of Directors. Dr. Cooney's extensive manufacturing and scale-up expertise, along with his business-building and corporate governance experience, will significantly contribute to the rapid commercialization of LS9 DesignerBiofuels™ products.

Adnexus Therapeutics

Adnexus Therapeutics Raises $15.5 Million in Series C Funding

Adnexus Therapeutics Raises $15.5 Million in Series C Funding

August 9, 2007

New Investor HBM BioVentures, Prominent Global Venture Firm, Leads Round

Waltham, MA – August 9, 2007 – Adnexus Therapeutics, Inc. today announced that it has raised $15.5 million through a private placement of Series C Preferred Stock. The financing was led by a new investor, HBM BioVentures (Cayman) Ltd., a leading global healthcare investment firm. All of Adnexus’ existing venture investors, Atlas Venture, Flagship Ventures, Polaris Venture Partners and Venrock, participated in the financing.

Technology Review Reveals the 2007 TR35 List of the 35 Top Young Innovators Under 35

Technology Review Reveals the 2007 TR35 List of the 35 Top Young Innovators Under 35

August 15, 2007

2007 Emerging Technologies Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Technology Review today announced the TR35 for 2007 – 35 accomplished men and women under the age of 35 who exemplify the spirit of innovation in business, technology and the arts. Doing ground-breaking work in energy, nanotechnology, biotechnology, computing, medicine, telecommunications and the Web, these young individuals stand out for their unique contributions to society.

Technology Review Unveils the 2007 TR35 Humanitarian and Innovator of the Year

Technology Review Unveils the 2007 TR35 Humanitarian and Innovator of the Year

August 15, 2007

Tapan Parikh from the University of Washington Named Humanitarian of the Year; David Berry of Flagship Ventures Named Innovator of the Year

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Technology Review today announced the 2007 Humanitarian and Innovator of the Year as part of its annual TR35 awards honoring the top 35 innovators under the age of 35. The Humanitarian of the Year honor goes to Tapan Parikh at the University of Washington, and the Innovator of the Year is David Berry, a principal at Flagship Ventures.

LS9

LS9 Co-founder Named Innovator of the Year in Technology Review's Prestigious TR35 List of Top Young Innovators

LS9 Co-founder Named Innovator of the Year in Technology Review's Prestigious TR35 List of Top Young Innovators

August 15, 2007

David Berry to be Honored at Technology Review's Emerging Technologies Conference at MIT

Flagship Ventures’ David Berry Named Technology Review’s Top Young Innovator

Flagship Ventures’ David Berry Named Technology Review’s Top Young Innovator

August 15, 2007

First Innovator of the Year from Venture Industry

Adnexus Therapeutics

Adnexus Therapeutics Announces Appointment of Timothy J. Rink, MD, ScD to Its Board of Directors

Adnexus Therapeutics Announces Appointment of Timothy J. Rink, MD, ScD to Its Board of Directors

August 21, 2007

Waltham, MA – August 21, 2007 – Adnexus Therapeutics, Inc. today announced Timothy J. Rink, MD, ScD has joined the Adnexus Board of Directors. Dr. Rink also currently serves as chairman of the Strategy Panel of the Technology Transfer division of the Wellcome Trust that funds biomedical research, and serves on the boards of Santhera Pharmaceuticals (SWX: SANN) and Sepracor, Inc. (NASDAQ: SEPR) and the scientific advisory board of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN).

Adnexus Therapeutics

Adnexus Therapeutics Files Registration Statement for Proposed Initial Public Offering

Adnexus Therapeutics Files Registration Statement for Proposed Initial Public Offering

August 21, 2007

Waltham, MA – August 21, 2007 – Adnexus Therapeutics, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. All shares in the offering will be sold by Adnexus.

The book-running managers of the proposed offering will be Lehman Brothers and UBS Securities LLC, and Cowen and Company and Lazard Freres & Co LLC will serve as co-managers.